Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03822117
Title	Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Incyte Corporation
Indications	Advanced Solid Tumor
Therapies	Pemigatinib
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU